ImmunoGen Management

Management criteria checks 2/4

ImmunoGen's CEO is Mark Enyedy, appointed in May 2016, has a tenure of 7.75 years. total yearly compensation is $5.42M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $18.25M. The average tenure of the management team and the board of directors is 1.3 years and 12.1 years respectively.

Key information

Mark Enyedy

Chief executive officer

US$5.4m

Total compensation

CEO salary percentage	14.0%
CEO tenure	7.8yrs
CEO ownership	0.2%
Management average tenure	1.3yrs
Board average tenure	12.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Enyedy's remuneration changed compared to ImmunoGen's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$74m
Jun 30 2023	n/a	n/a	-US$180m
Mar 31 2023	n/a	n/a	-US$240m
Dec 31 2022	US$5m	US$759k	-US$223m
Sep 30 2022	n/a	n/a	-US$201m
Jun 30 2022	n/a	n/a	-US$161m
Mar 31 2022	n/a	n/a	-US$129m
Dec 31 2021	US$7m	US$735k	-US$139m
Sep 30 2021	n/a	n/a	-US$71m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$5m	US$714k	-US$44m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$4m	US$710k	-US$104m
Sep 30 2019	n/a	n/a	-US$151m
Jun 30 2019	n/a	n/a	-US$176m
Mar 31 2019	n/a	n/a	-US$174m
Dec 31 2018	US$9m	US$687k	-US$169m
Sep 30 2018	n/a	n/a	-US$140m
Jun 30 2018	n/a	n/a	-US$150m
Mar 31 2018	n/a	n/a	-US$117m
Dec 31 2017	US$3m	US$670k	-US$96m

Compensation vs Market: Mark's total compensation ($USD5.42M) is above average for companies of similar size in the UK market ($USD3.17M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Enyedy (59 yo)

7.8yrs

Tenure

US$5,422,421

Compensation

Mr. Mark Joseph Enyedy serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. He is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Enyedy	President	7.8yrs	US$5.42m	0.22% $ 18.3m
Stacy Coen	Senior VP & Chief Business Officer	3.7yrs	US$1.84m	0.027% $ 2.3m
Michael Vasconcelles	Chief Medical Officer	1.2yrs	US$3.81m	0.00050% $ 41.8k
Lauren White	Senior VP & Chief Financial Officer	less than a year	no data	no data
Anabel Chan	Head of Investor Relations	no data	no data	no data
Daniel Char	Senior VP	1.3yrs	no data	0.00037% $ 30.9k
Courtney O'Konek	Senior Director of Corporate Communications & Investor Relations	no data	no data	no data
Audrey Bergan	Senior VP & Chief HR Officer	5.6yrs	no data	no data
Theresa Wingrove	Senior Vice President of Regulatory Affairs & Quality	no data	US$1.27m	0.0079% $ 657.0k
Isabel Kalofonos	Senior VP & Chief Commercial Officer	less than a year	no data	no data

1.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: 0A8K's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Enyedy	President	7.8yrs	US$5.42m	0.22% $ 18.3m
Stephen McCluski	Independent Chairman	16.8yrs	US$257.80k	0% $ 0
Dean Mitchell	Independent Director	12.1yrs	US$217.80k	0.038% $ 3.2m
Kristine Peterson	Independent Director	12.1yrs	US$227.80k	0% $ 0
Helen Thackray	Independent Director	2.4yrs	US$175.00k	0.0011% $ 96.1k
Richard Wallace	Independent Director	16.3yrs	US$220.30k	0.0037% $ 312.6k
Stuart Arbuckle	Independent Director	6.1yrs	US$210.30k	0.0020% $ 168.0k
Mark A. Goldberg	Independent Director	12.3yrs	US$225.30k	0.023% $ 1.9m
Tracey McCain	Independent Director	2.3yrs	US$146.65k	0% $ 0

12.1yrs

Average Tenure

64yo

Average Age

Experienced Board: 0A8K's board of directors are seasoned and experienced ( 12.1 years average tenure).

ImmunoGen Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold US$1.5m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold US$17m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

Forecast breakeven date moved forward to 2024

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age